DAX-0,05 % EUR/USD-0,35 % Gold-0,45 % Öl (Brent)-0,77 %

Pfizer-Pharmawert total unterbewertet! 50% möglich! (Seite 88)


WKN: 852009 | Symbol: PFE
38,59
08:00:18
Hamburg
-0,62 %
-0,24 EUR

Begriffe und/oder Benutzer

 

Pfizer hikes prices on dozens of drugs for second time this year
https://www.marketwatch.com/story/pfizer-hikes-prices-on-doz…

=>
...Pfizer Inc. raised the list prices for more than 40 of its prescription drugs this week, marking a second round of increases this year despite mounting public scrutiny.

The increases apply to widely used drugs including lung-cancer treatment Xalkori, Norvasc blood-pressure pills and Lyrica pain capsules, according to drug-pricing data from RELX PLC’s Elsevier information business. Many lift the list prices by 9.4% and by double-digit percentages for the year overall.

The moves, which were first reported by the Financial Times, separate Pfizer from several rivals that have pledged to lift list prices only once every 12 months and by less than 10% overall for the year, as they try to blunt criticism and avoid congressional action.

Pfizer, one of the world’s biggest drug companies by sales, said it commonly sells its products at a discount and isn’t responsible for how much patients must bear in copays or other out-of-pocket costs.
Antwort auf Beitrag Nr.: 58.121.099 von faultcode am 03.07.18 01:28:32
Umbau
https://www.wallstreet-online.de/nachricht/10713059-pfizer-b…
https://www.finanzen.net/nachricht/aktien/pfizer-will-mit-um…

=>
(a)
Der US-Pharmariese Pfizer will umbauen und sich künftig in drei Sparten aufstellen. Ab dem Geschäftsjahr 2019 gehören zur forschenden Sparte neuartige Medikamente und sogenannte Biosimilars, wie Pfizer am Mittwoch in New York mitteilte. Das Geschäft soll in einem neuen Bereich auch Krankenhäuser mit Anti-Infektionsmitteln versorgen.

Die beiden weiteren Sparten kümmern sich zum einen um patentfreie und Nachahmer-Mittel sowie zum anderen um rezeptfreie Arzneien. Ab 2020 erwarte das Unternehmen ein stärkeres und stabileres Wachstum, weil die Belastungen aus Patentausläufen zurückgingen, sagte Pfizer-Chef Ian Read. Darauf sei die neue Struktur ausgerichtet. Das meiste Geld verdienen Pharmakonzerne mit eigenen patentgeschützten Medikamenten. Biosimilars sind forschungsintensive Folgepräparate von Biopharmazeutika, deren Patentschutz ausgelaufen ist.

Die Generikasparte soll bei Pfizer nun weitgehend unabhängig vom Restkonzern agieren können. Das Geschäft mit rezeptfreien Mitteln wiederum hatte der Konzern vergangenes Jahr eigentlich zum Verkauf gestellt, allerdings hatte kein Käufer ausreichenden Appetit gezeigt - Reckitt Benckiser und GlaxoSmithKline hatten nach Gesprächen abgewunken.


——


(b)
Damit sollen die erwarteten Auswirkungen durch den Patentschutzverlust für das Nervenschmerzmittel Lyrica in den USA beträchtlich verringert werden, wie die Pfizer Inc mitteilte.
...
Die neue Struktur soll bis Anfang des Geschäftsjahres 2019 umgesetzt sein. Auf die Kapitalallokation oder die Prognose für das Jahre 2018 werde dies keine Auswirkungen haben.
Antwort auf Beitrag Nr.: 58.189.391 von faultcode am 11.07.18 17:55:49
Pfizer, Eli Lilly non-opioid pain drug nears finish line
July 18, 2018 10:32 a.m. ET
https://www.marketwatch.com/story/pfizer-eli-lilly-non-opioi…
=>
...A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. and Eli Lilly & Co. had positive early results in a phase 3 clinical trial, the companies announced on Wednesday.

The drug, tanezumab, met all three co-primary endpoints in the trial. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo.

Nearly 700 patients were enrolled in the trial, which was 16 weeks long, randomized and double-blind. Safety issues have been a longtime concern with the drug, but the companies said early data did not reveal any problems. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.

This class of drugs has previously worked almost too well for patients, such that their osteoarthritis has worsened, requiring joint replacements. Investors should watch for a 3,000 patient, 52-week trial, for which results are expected this fall, Raffat added.

Pfizer and Eli Lilly are also developing tanezumab for chronic lower back pain and cancer pain, and the drug has "fast track" designation from the Food and Drug Administration for the osteoarthritis and lower back pain indications....
Pfizer zieht durch
eigentlich "Pfizer zog durch" ;)



=> der Earnings Beat von Ende Juli ist (mMn) - wie so oft - nachgeschoben
--> ich gehe von einer Rotation in "Value" aus (obwohl PFE auch nur Piotroski F-Score 6/9 z.Z. hat)

=> daher bin ich optimistischer (als zuletzt), was diesmal das Halten des erhöhten Kurs-Levels angeht...
Antwort auf Beitrag Nr.: 58.372.572 von faultcode am 03.08.18 23:23:03das mit der "Value"-Rotation gilt (mMn) im Grunde genommen für viele Big Pharmawerte seit so 2018Q1

=> z.B.:
• Ausverkauf Sanofi beendet
• Roche auch mit Rebound
• ...
Antwort auf Beitrag Nr.: 58.372.614 von faultcode am 03.08.18 23:31:02
Proof: 3D Value vs Growth ratio, 2008-2018
EpiPen shortage - und Pfizer mittendrin
14.8.
There’s an EpiPen shortage — and parents fear for their allergic kids
https://www.marketwatch.com/story/epipen-shortage-could-turn…

=>
...
The problems date back to major manufacturing issues at a Missouri facility that is run by Meridian Medical Technologies Inc., a Pfizer Inc. unit. All U.S. EpiPen products are manufactured at that factory, Pfizer confirmed.

Meridian Medical Technologies “failed to thoroughly investigate multiple serious component and product failures... including failures associated with patient deaths and severe illness,” according to a Food and Drug Administration warning letter that was sent to the company in September.

The warning letter itself didn’t affect supply, Pfizer spokesperson Steve Danehy told MarketWatch in an email, but “new processes” put into place to fix the problems noted in the warning letter have had “some impact on manufacturing capacity.”

Supply of third-party components has also played a role, Danehy said, and he described supply problems as temporary.

Supply problems for a rival product, Amneal’s Adrenaclick, were due to a shortage of supply coming out of a third-party manufacturer — also Pfizer, Amneal Chief Executive Robert Stewart said on a recent conference call, calling it an “unfortunate situation.”

The supply problems, which Amneal has said relate to compliance issues at Pfizer, Pfizer’s 2015 acquisition of injectable-drug maker Hospira and challenges at the Hospira manufacturing operation, continued through the second quarter and last month.

As for what is behind these manufacturing challenges, FARE’s Madsen said her organization’s understanding is that “putting [epinephrine] into an autoinjector that is reliable and will fire when you need it to is a little bit of a technically-challenging manufacturing detail.”

Both Pfizer and Mylan have said that they are exploring stabilization options, though they haven’t explained what those might be nor provided a specific timeline; Amneal says it has been working with Pfizer....
Pfizer-Chef Read tritt zum Jahreswechsel zurück --> Eigengewächs Albert Bourla soll kommen
1.10.
https://www.wallstreet-online.de/nachricht/10896909-pfizer-c…

=>
...Der langjährige Pfizer -Chef Ian Read tritt von seinem Amt zurück. Zum 1. Januar 2019 werde er die Konzernführung an den bisher für das operative Geschäft zuständigen Vorstand Albert Bourla abgeben, teilte der Konzern am Montag in New York mit.

Read bleibt dem Pharmariesen aber erhalten und wird Verwaltungsratschef. Zuvor hatte das "Wall Street Journal" über den Wechsel an der Unternehmensspitze berichtet. Read leitet den Konzern seit acht Jahren. Es sei nun an der Zeit, einen Wechsel an der Spitze einzuläuten, erklärte Read laut Mitteilung...



=>
...Albert has over 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines...
https://www.pfizer.com/people/leadership/executives/albert_b…
echte "Rakete" hier mittlerweile:




Einfaches Einfügen von wallstreet:online Charts: So funktionierts.
Antwort auf Beitrag Nr.: 58.883.379 von faultcode am 05.10.18 23:06:08
FDA approves Pfizer's drug for advanced breast cancer
https://finance.yahoo.com/news/fda-approves-pfizers-drug-adv…

=>
...The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

The drug, talazoparib, belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

The PARP market is currently dominated by AstraZeneca's cancer drug Lynparza.

Talazoparib, a once-daily pill that Pfizer acquired with its $14 billion purchase of Medivation in 2016, is indicated for breast cancer triggered by mutation of BRCA genes, which accounts for 25-30 percent of hereditary breast cancers and 5-10 percent of all breast cancers....
 Durchsuchen


Beitrag zu dieser Diskussion schreiben